Collective formal synthesis of (±)-rhynchophylline and homologues

Jun Xua, Li-Dong Shao*a, Xin Shiab, Jian Renab, Chengfeng Xia*a and Qin-Shi Zhao*a
aState Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650201, People's Republic of China. E-mail: qinshizhao@mail.kib.ac.cn; xiachengfeng@mail.kib.ac.cn; shaolidong@mail.kib.ac.cn
bUniversity of Chinese Academy of Sciences, Beijing 100049, People's Republic of China

Received 17th May 2016 , Accepted 25th June 2016

First published on 28th June 2016


Abstract

A collective formal synthesis approach to bioactive oxindole alkaloids, including (±)-rhynchophylline, (±)-isorhynchophylline, (±)-mitraphylline, (±)-formosanine, (±)-isomitraphylline, and (±)-isoformosanine, is completed in a protecting-group free manner. Besides multigram-scaled operations, the notable feature of the synthesis is the application of two one-pot, sequential transformations. Namely, two key tetracyclic intermediates pyridinium salt 9 and monoester 14 were prepared by a one-pot N-alkylation/cross-dehydrogenative coupling sequence and a one-pot Michael/Karpocho sequence with minimal purification, respectively.


Introduction

Rhynchophylline (1, Fig. 1) and isorhynchophylline (2) are tetracyclic 3-spirooxindole alkaloids isolated from Uncaria rhynchophylla.1,2 Investigation of the pharmacological effects of rhynchophylline (1) and isorhynchophylline (2) reveal that they exert beneficial effects on cardiovascular disease including hypertension, bradycardia, and arrhythmia. Rhynchophylline (1) and isorhynchophylline (2) both act as Ca2+ channel antagonists, anticoagulants, and vascular smooth muscle cell proliferation inhibitors.3 Moreover, rhynchophylline (1) has been identified as an inhibitor of the receptor tyrosine kinase EphA4, and is implicated in rescuing hippocampal synaptic dysfunctions in AD.4,5
image file: c6ra12766e-f1.tif
Fig. 1 Rhynchophylline and its homologues.

The biological significance and structural complexity of 3-spirooxindole moiety prompted synthetic organic chemists to take up the research project towards the synthesis of rhynchophylline (1) and its homologues (2–8).6,7 Ban et al. achieved the first total synthesis of (±)-1 and (±)-2 via an intramolecular Mannich reaction starting form 2-hydroxytryptamine hydrochloride within 10 steps.6a With the same strategy, Ban et al. completed the synthesis of (±)-mitraphylline (3), (±)-formosanine (4), (±)-isomitraphylline (5), and (±)-isoformosanine (6).6b Martin et al. reported a biomimic formal synthesis of (±)-1 and (±)-2 over 15 steps which 3-spirooxindole tetracyclic fragment was constructed by the oxidation rearrangement of Corynanthe indole intermediate.6c Recently, two enantioselective approaches to 1 and 2 were established by Wang et al.6d and Amat et al.6e in 20 and 18 steps, respectively. Hiemstra et al. reported a collective synthesis of (±)-1, (±)-corynoxine (7), (±)-corynoxine B (8), and (±)-corynoxeine involving an intramolecular Mannich reaction as a key step.6f More recently, we described a cross-dehydrogenative coupling (CDC) approach which provided the direct access to the tetracyclic 3-spirooxindole system and to the application in the facile synthesis of (±)-7 and (±)-8.7 Herein, a collective formal synthesis of six oxindole alkaloids including rhynchophylline (1) and its homologues (2–6) was completed based upon a one-pot N-alkylation/cross-dehydrogenative coupling sequence and a one-pot stereoselective Michael/Karpocho sequence.

Results and discussion

As outlined in Scheme 1, oxindole alkaloids 1–6 could be transformed from Ban's intermediates (16–18)6a,6b and the collective synthesis strategy of them was focused on controlling the stereoselectivity of the functionalization mode of C15 and C20. Unlike corynoxine (7) and corynoxine B (8) which the cis-substituents of C15 and C20 were installed by Johnson–Claisen rearrangement of allylic alcohol 12 with trimethyl orthoacetate in situ.7 The trans-substituents of C15 and C20 of 1–6 could be introduced by a one-pot stereoselective Michael/Krapcho sequence of ketone 13 with methyl malonate. Intermediates 12 and 13 could be formed by dearomatization of pyridinium salt 9. Compound 9 could be prepared by an improved one-pot N-alkylation/CDC sequence of 3-(2-bromoethyl)indolin-2-one (11) which was prepared from tryptophol in 2 steps according to the literature.7
image file: c6ra12766e-s1.tif
Scheme 1 Synthesis strategy of rhynchophylline and its homologues.

The collective synthesis commenced with the multigram-scaled preparation of intermediate 12 and 13 which was shown in Scheme 2. Oxidation of commercially available tryptophol followed by bromination with N-bromosuccinimide (NBS) provided 3-(2-bromoethyl)indolin-2-one (11) in 69.6% yield over 2 steps.7 Then an improved synthesis of 12 and 13 started from a one-pot N-alkylation/CDC protocol which was initiated by heating 11 with 3-acetyl pyridine (10) at 70 °C for 3 h, removing the unreacted 3-acetyl pyridine by adding large amount of ether that contained 10% of MeOH, pouring out of the solvent after stirring vigorously for 30 min. The rest ether was evaporated to give the residue in the flask. Adding Na2CO3 and MeCN into the flask, connecting to an oxygen balloon, the reaction was heated at 50 °C for 12 h to give pyridinium salt 9 in 56% yield over two-steps in one-pot after one purification operation. Subsequently, dearomatization of 9 in dioxane/water with NaBH4 afforded the intermediate 12 in 78% yield as previously reported.7 Interestingly, the reaction was also proceeded smoothly in water without organic solvent to give 12 in 79% yield (Scheme 2).8 Otherwise, dearomatization of 9 by NaBH3CN in THF/AcOH gave ketone 13 in 30% yield.


image file: c6ra12766e-s2.tif
Scheme 2 An improved synthesis of intermediate 12 and 13.

Next ketone 13 was converted to Ban's intermediate 16 (ref. 6a) through a series of transformations. As depicted in Scheme 3, ketone 13 could be also prepared by oxidation of allylic alcohol 12 with Dess–Martin periodinane (DMP) in 80% yield.8 Next, a one-pot protocol started from the stereoselective Michael addition reaction of methyl malonate to 13 in the presence of MeONa (1 N).6b,9 After evaporation of MeOH, removing one of the methyl esters under Krapcho's condition by heating the crude diester with LiCl in DMSO at 150 °C gave the key trans-C15,20 substituted keto-monoester 14 in 53% yield over two-reactions in one pot.10,11 Treating 14 with 1,2-ethanedithiol in the presence of BF3·Et2O furnished dithioether 15, which was underwent the desulfuration by RANEY®-Ni to give the desired Ban's intermediate 16 in 81% yield.12–15 Compound 16 could be converted into alkaloids (±)-2 and (±)-1 in 2 and 3 steps, respectively.6a,7 The spectral data of 16 was identical to those reported in the literature by Martin and Wang.6c,6d


image file: c6ra12766e-s3.tif
Scheme 3 Formal synthesis of (±)-rhynchophylline and (±)-isorhynchophylline.

With compound 14 in hand, both Ban's intermediates 17 and 18 (ref. 6b) could be prepared by diastereoselective hydrogenation of the carbonyl group of 14 (Scheme 4). On one hand, treatment of the monoester 14 with NaBH4 at −40 °C, followed by heating in benzene with TsOH resulted in the desired lactone compound 17 as a single diastereomer in 69% yield over 2 steps, which was further converted into (±)-5 and (±)-3 in 3 and 4 steps, respectively.6b,7 On the other hand, diastereoselective hydrogenation of the monoester 14 with Adam's catalyst in acetic acid resulted in the desired lactone compound 18 as a single diastereomer in 60% yield, which was also further converted into (±)-6 and (±)-4 in 3 and 4 steps, respectively.6b,7 The spectroscopic data of compound 17 and 18 were identical to that reported in the literature.6b


image file: c6ra12766e-s4.tif
Scheme 4 Formal synthesis of (±)-mitraphylline, (±)-isomitraphylline, (±)-formosanine and (±)-isoformosaninec.

Conclusions

In summary, we have accomplished a collective synthesis route to six oxindole alkaloids including (±)-rhynchophylline (1), (±)-isorhynchophylline (2), (±)-mitraphylline (3), (±)-formosanine (4), (±)-isomitraphylline (5), and (±)-isoformosanine (6) within 10 steps from the pyridinium salt 9. The highlighted feature of the synthesis is the application of protecting-group free strategy throughout the synthesis, a one-pot N-alkylation/CDC protocol to furnish key intermediate pyridinium salt 9, and a one-pot Michael/Karpocho protocol to establish the common intermediate 14. Furthermore, many operations could be performed in multigram scale. We anticipate that outlined concise approach can be exploited for the synthesis of other numbers of bioactive tetracyclic 3-spirooxindole alkaloids. Efforts of our laboratory in this field will be reported in due course.

Experimental section

General experimental procedures

Anhydrous THF, Et2O, toluene and benzene were distilled over sodium and benzophenone ketyl under N2; Et3N, DCM and CH3CN were refluxed with CaH2 and freshly distilled prior to use; anhydrous MeOH and EtOH were distilled over magnesium under Ar; all other solvents and reagents were used from commercial sources without further purifications. All reactions sensitive to air or moisture were carried out under argon or nitrogen atmosphere in dry and freshly distilled solvents under anhydrous conditions, unless otherwise noted.

1H NMR and 13C NMR experiments were performed on Bruker Avance 400, 600 and 800 NMR spectrometer at ambient temperature. The residual solvent protons (1H) or the solvent carbons (13C) were used as internal standards. 1H NMR data were presented as follows: chemical shift in ppm downfield from tetramethylsilane (multiplicity, coupling constant, integration). Chemical shifts (δ) were given in ppm with reference to solvent signals [1H NMR: CDCl3 (7.26), DMSO-d6 (2.50); 13C NMR: CDCl3 (77.16), DMSO-d6 (39.52)]. The following abbreviations are used in reporting NMR data: s, singlet; brs, broad singlet; d, doublet; t, triplet; q, quartet; qt, quartet of triplets; dd, doublet of doublets; dt, doublet of triplets; AB, AB quartet; m, multiplet. HRMS (ESI) was taken on Agilent 6540 Q-TOF spectrometer.

An improved one-pot N-alkylation-CDC sequential protocol to pyridinium salt 9. A suspension of 3-(2-bromo-ethyl)-indole 11 (5 g, 21.0 mmol) and 3-acetyl pyridine (12.7 g, 105.0 mmol) was vigorously stirred at 70 °C for 3 h. The mixture was cooled to room temperature. Ethyl ether (60 mL, contained 6 mL MeOH) was added. The mixture was stirred vigorously for 10 min until the pasty material solidified then decanted the organic layer, this procedure was repeated for three times. The residue yellow wax was evaporated on the evaporator to remove the rest of solvent. Na2CO3 (1.10 g, 10.5 mmol) and MeCN (100 mL) was added into the flask and stirred vigorously at room temperature under an atmosphere of oxygen (1 atm) for 12 h. The mixture was concentrated in vacuum to leave the residue, which was subjected to flash chromatographic separation (DCM[thin space (1/6-em)]:[thin space (1/6-em)]methanol = 20[thin space (1/6-em)]:[thin space (1/6-em)]1) to afford product 9 (4.2 g, 56%) as a yellow foam. 1H NMR (400 MHz, CD3OD): δ 9.73 (s, 1H), 8.90 (dd, J = 8.3, 1.0, 1H), 7.65 (d, J = 8.4, 1H), 7.39 (dt, J = 7.9, 5.0, 2H), 7.19–6.95 (m, 2H), 5.39–5.21 (m, 2H), 3.07 (dd, J = 8.5, 6.3, 2H), 2.72 (s, 3H); 13C NMR (100 MHz, CD3OD): δ 192.8, 175.7, 159.6, 145.4, 143.4, 142.6, 135.4, 130.6, 128.3, 124.6, 123.5, 123.5, 110.7, 60.0, 58.2, 48.3, 48.1, 47.8, 47.6, 47.4, 47.2, 47.0, 33.8, 25.9; HRMS (ESI+): calcd for C17H15N2O2 [M]+ 279.1134; found 279.1134.
Allylic alcohol 12. To a solution of NaBH4 (0.51 g, 13.4 mmol) in water (100 mL) at room temperature was added dropwise of 9 (1.20 g, 3.4 mmol) in 500 mL of boiling water. After being stirred at room temperature for 0.5 h, the reaction mixture was poured into saturated NH4Cl aqueous solution, the resulting solution was extracted with DCM (3 × 100 mL). The combined organic layers were washed with brine (3 × 100 mL), dried over Na2SO4. After removal of the solvent, the residue was purified by flash column chromatography on silica gel (DCM/methanol = 50[thin space (1/6-em)]:[thin space (1/6-em)]1) to give allylic alcohol 12 (0.74 g, 79%) as a yellow foam. 1H NMR (400 MHz, CDCl3): δ 8.86 (s, 1H), 7.42–7.32 (m, 1H), 7.18 (t, J = 7.6 Hz, 1H), 7.01 (td, J = 7.4, 2.6 Hz, 1H), 6.90 (d, J = 7.7 Hz, 1H), 5.57 (d, J = 28.9 Hz, 1H), 4.34–4.13 (m, 1H), 3.64 (dd, J = 63.7, 15.5 Hz, 1H), 3.47 (t, J = 8.6 Hz, 1H), 2.97–2.84 (m, 1H), 2.82–2.71 (m, 1H), 2.63 (ddd, J = 17.7, 8.8, 4.1 Hz, 1H), 2.49–2.41 (m, 1H), 2.11 (dt, J = 12.9, 8.5 Hz, 1H), 1.78–1.60 (m, 2H), 1.28 (dd, J = 6.3, 4.4 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 182.4, 140.5, 140.1, 139.9, 133.4, 127.9, 125.3, 122.6, 119.8, 118.1, 109.8, 70.4, 69.6, 68.1, 68.0, 56.6, 54.5, 53.2, 51.9, 35.4, 35.3, 26.6, 26.5, 22.3, 21.7; HRMS (ESI) m/z calcd for C17H21N2O2 [M + H]+ 285.1598, found 285.1598.
Ketone 13 (preparation from pyridinium salt 9). To a solution of 9 (1.0 g, 2.8 mmol) in THF/AcOH (10[thin space (1/6-em)]:[thin space (1/6-em)]1, v/v, 100 mL) was added NaBH3CN (350 mg, 5.6 mmol) in portions at 0 °C, the temperature was gradually rised to room temperature, and stirred for 12 h. The reaction mixture was poured into saturated NH4Cl aqueous solution, the resulting solution was extracted with DCM (3 × 100 mL). The combined organic layers were washed with brine (3 × 100 mL), dried over Na2SO4, after removal of the solvent, the residue was purified by flash column chromatography on silica gel (DCM/methanol = 80[thin space (1/6-em)]:[thin space (1/6-em)]1) to give ketone 13 (245 mg, 30%) as a colorless oil (spectra data is listed below).
Ketone 13 (preparation from allylic alcohol 12). To a solution of allylic alcohol 12 (2.05 g, 7.2 mmol) in DCM (50 mL) at 0 °C, were successively added NaHCO3 (667 mg, 7.9 mmol) and Dess–Martin periodinane (3.37 mg, 7.9 mmol). After stirring at RT for 2 h, the reaction mixture was hydrolyzed with a 1.5 M aqueous solution of Na2S2O3 (50 mL) and a saturated aqueous solution of NaHCO3 (50 mL). After extraction with DCM (3 × 100 mL), the combined extracts were washed with brine, dried over MgSO4, filtered, and concentrated under reduced pressure. The crude material was purified by flash chromatography (DCM/methanol = 80[thin space (1/6-em)]:[thin space (1/6-em)]1) to afford ketone 13 (1.62 g, 80%) as a colorless oil. 1H NMR (400 MHz, CDCl3): δ 8.45 (s, 1H), 7.35 (d, J = 7.3 Hz, 1H), 7.22 (t, J = 7.6 Hz, 1H), 7.04 (t, J = 7.5 Hz, 1H), 6.92 (d, J = 7.7 Hz, 1H), 6.76 (s, 1H), 3.98 (d, J = 16.4 Hz, 1H), 3.52 (dd, J = 8.5, 6.0 Hz, 1H), 2.94 (d, J = 16.0 Hz, 1H), 2.77 (dd, J = 9.0, 4.8 Hz, 1H), 2.73–2.63 (m, 1H), 2.54–2.44 (m, 1H), 2.27 (s, 3H), 2.11 (dt, J = 13.2, 7.8 Hz, 1H), 1.92 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 182.4, 140.5, 140.1, 139.9, 133.4, 127.9, 125.3, 122.6, 119.8, 118.1, 109.8, 70.4, 69.6, 68.1, 68.0, 56.6, 54.5, 53.2, 51.9, 35.4, 35.3, 26.6, 26.5, 22.3, 21.7; HRMS (ESI) m/z calcd for C17H19N2O2 [M + H]+ 283.1441, found 283.1443.
A one-pot Michael–Krapcho sequential protocol to keto-monoester 14. Dimethyl malonate (2.06 mL, 18.1 mmol) was added to solution of sodium methoxide (1.81 mL, 1.8 mmol, MeONa 1 N in MeOH). To the solution was added a solution of the ketone 13 (1.02 g, 3.6 mmol) in dry MeOH (10 mL). After being stirred for 12 h at room temperature, the MeOH was evaporated under reduced pressure at 30 °C to give crude diester in the flask. DMSO (25 mL), deionized water (260 μL, 14.4 mmol), and LiCl (200 mg, 4.8 mmol) were added, the mixture was stirred at 150 °C for 4.5 h. The reaction was worked up by addition of DCM (60 mL), and the mixture was washed with water (3 × 50 mL). The organic layers were washed with brine, dried over Na2SO4. The solvent was removed under vacuum, and the residue was purified by a flash chromatography on silica gel (DCM/methanol = 80[thin space (1/6-em)]:[thin space (1/6-em)]1) to give product keto-monoester 14 (680 mg, 53%) as a white foam. 1H NMR (400 MHz, CDCl3): δ 8.06 (s, 1H), 7.34 (d, J = 7.4 Hz, 1H), 7.20 (t, J = 7.3 Hz, 1H), 7.03 (t, J = 7.4 Hz, 1H), 6.88 (d, J = 7.7 Hz, 1H), 3.53 (s, 3H), 3.31 (ddd, J = 10.5, 9.6, 2.8 Hz, 2H), 2.61 (td, J = 11.0, 3.6 Hz, 1H), 2.52 (dd, J = 10.5, 6.8 Hz, 2H), 2.45–2.37 (m, 1H), 2.23 (d, J = 4.2 Hz, 1H), 2.19 (s, 3H), 2.17–2.12 (m, 1H), 2.11–1.95 (m, 3H), 1.39–1.33 (m, 1H), 0.73 (q, J = 11.9 Hz, 1H). 13C NMR (100 MHz, CDCl3): δ 209.8, 181.4, 172.3, 140.4, 133.4, 127.9, 125.1, 122.6, 109.8, 70.9, 56.7, 55.0, 54.9, 53.6, 51.6, 38.5, 35.3, 33.9, 31.1, 30.0; HRMS (ESI) m/z calcd for C20H24N2O4 [M + H]+ 357.1809, found 357.1814.
Dithioketal 15. To a solution of keto-monoester 14 (40 mg, 0.11 mmol) in DCM (2 mL) at 0 °C was added 1,2-ethanedithiol (211 μL, 2.20 mmol) and boron trifluoride diethyl etherate (144 μL, 1.10 mmol). The bath was removed and the mixture was stirred at room temperature for 8 h. The resultant solution was treated with 2 M aqueous NaHCO3 and extracted with DCM (3 × 5 mL). The combined organic extracts were washed with brine, dried over Na2SO4, filtered, concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (DCM/methanol = 80[thin space (1/6-em)]:[thin space (1/6-em)]1) to give dithioketal 15 (41 mg, 86%) as a colorless oil. 1H NMR (400 MHz, CDCl3): δ 8.47 (s, 1H), 7.38 (d, J = 7.3 Hz, 1H), 7.18 (t, J = 7.3 Hz, 1H), 7.01 (t, J = 7.3 Hz, 1H), 6.88 (d, J = 7.7 Hz, 1H), 3.67–3.60 (m, 1H), 3.55 (s, 3H), 3.44–3.35 (m, 1H), 3.29 (ddt, J = 16.4, 10.7, 5.2 Hz, 3H), 3.20–3.10 (m, 1H), 2.96 (dd, J = 15.5, 2.8 Hz, 1H), 2.57–2.43 (m, 2H), 2.43–2.34 (m, 1H), 2.04 (dddd, J = 32.6, 24.2, 11.9, 6.8 Hz, 5H), 1.69 (s, 3H), 1.24 (dd, J = 9.4, 3.0 Hz, 1H), 0.86 (dd, J = 23.6, 11.7 Hz, 1H); 13C NMR (100 MHz, CDCl3): δ 181.6, 172.8, 140.2, 133.6, 127.8, 125.2, 122.6, 109.7, 71.0, 69.3, 58.0, 56.7, 53.6, 51.9, 51.6, 40.5, 39.5, 37.1, 36.1, 35.6, 32.2, 29.4; HRMS (ESI) m/z calcd for C22H29N2O3S2 [M + H]+ 433.1614, found 433.1618.
Monoester 16. To a solution of dithioketal 15 (16 mg, 0.04 mmol) in MeOH/THF (2[thin space (1/6-em)]:[thin space (1/6-em)]1, v/v, 1.5 mL) was added excess RANEY®-Ni (W-2 type, newly activated). After refluxed at 105 °C for 4.5 h, the reaction mixture was filtered through a plug of Celite, the filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (DCM/methanol = 80[thin space (1/6-em)]:[thin space (1/6-em)]1) to give 16 (10 mg, 81%) as a colorless oil. 1H NMR (600 MHz, DMSO-d6): δ 10.36 (s, 1H), 7.22 (d, J = 7.3 Hz, 1H), 7.15 (td, J = 7.6, 1.2 Hz, 1H), 6.95 (td, J = 7.5, 0.8 Hz, 1H), 6.81 (d, J = 7.7 Hz, 1H), 3.47 (s, 3H), 3.25–3.17 (m, 2H), 2.47 (dd, J = 15.6, 3.4 Hz, 1H), 2.30 (dd, J = 17.4, 8.7 Hz, 1H), 2.22 (d, J = 10.7 Hz, 1H), 2.17 (t, J = 11.0 Hz, 1H), 1.92–1.77 (m, 2H), 1.69 (t, J = 10.9 Hz, 1H), 1.49 (dd, J = 11.5, 7.2 Hz, 1H), 1.43–1.35 (m, 1H), 1.16 (d, J = 9.4 Hz, 1H), 1.09–0.97 (m, 2H), 0.83 (dd, J = 14.1, 6.7 Hz, 3H), 0.60 (q, J = 11.8 Hz, 1H); 13C NMR (150 MHz, DMSO-d6): δ 180.1, 172.8, 141.4, 133.6, 127.5, 124.5, 121.5, 109.2, 71.0, 57.0, 56.0, 53.4, 51.2, 40.6, 37.4, 36.7, 34.7, 31.6, 22.9, 10.9; HRMS (ESI) m/z calcd for C20H27N2O3 [M + H]+ 343.2016, found 343.2022.
Lactone 17. To a solution of keto-monoester 14 (38 mg, 0.11 mmol) in MeOH (2 mL) at −40 °C was added a solution of NaBH4 (7 mg, 0.22 mmol) in MeOH (1 mL). After stirring for 2 h, the reaction mixture was poured into saturated NH4Cl aqueous solution, the resulting solution was extracted with DCM (3 × 5 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered, after removal of the solvent, the residue was subjected to flash column chromatography (DCM/methanol = 80[thin space (1/6-em)]:[thin space (1/6-em)]1) to afford the reduction product as a colorless oil. This oil was dissolved in benzene (2 mL). To this solution was added TsOH (37 mg, 0.22 mmol) at room temperature. After the reaction was refluxed at 85 °C for 3 h, benzene was removed in vacuo. The residue was diluted with DCM (2 mL) and water (1 mL). The aqueous layer was extracted with DCM (3 × 5 mL), and the combined organic layers were washed with brine, dried over Na2SO4, after removal of the solvent. The crude material was purified by flash chromatography (DCM/methanol = 80[thin space (1/6-em)]:[thin space (1/6-em)]1) to afford 17 (24 mg, 69%) as a colorless oil. 1H NMR (600 MHz, CDCl3): δ 7.54 (s, 1H), 7.36 (d, J = 7.4 Hz, 1H), 7.22 (t, J = 7.7 Hz, 1H), 7.05 (t, J = 7.5 Hz, 1H), 6.87 (d, J = 7.7 Hz, 1H), 4.67 (m, 1H), 3.33 (t, J = 7.8 Hz, 1H), 3.16 (dd, J = 10.3, 2.8 Hz, 1H), 2.55 (dt, J = 13.1, 6.8 Hz, 2H), 2.48 (d, J = 11.3 Hz, 1H), 2.42 (t, J = 11.2 Hz, 1H), 2.06 (dt, J = 13.1, 8.5 Hz, 1H), 2.02–1.88 (m, 3H), 1.84 (dt, J = 16.1, 5.7 Hz, 1H), 1.37 (d, J = 12.5 Hz, 1H), 1.29 (d, J = 6.7 Hz, 3H), 0.69 (q, J = 11.5 Hz, 1H); 13C NMR (150 MHz, CDCl3): δ 180.9, 170.2, 140.0, 133.3, 128.1, 125.2, 122.9, 109.6, 77.6, 70.9, 56.4, 54.1, 54.0, 39.8, 36.6, 35.2, 32.6, 28.7, 17.7; HRMS (ESI) m/z calcd for C19H23N2O3 [M + H]+ 327.1703, found 327.1704. For observation of –NH: 1H NMR (800 MHz, DMSO-d6) δ 10.35 (–NH, s, 1H), 7.17 (d, J = 7.3 Hz, 1H), 7.10 (t, J = 7.5 Hz, 1H), 6.90 (t, J = 7.4 Hz, 1H), 6.77 (d, J = 7.7 Hz, 1H), 4.60–4.53 (m, 1H), 3.19 (dd, J = 8.4, 6.5 Hz, 1H), 3.06 (dd, J = 10.5, 3.2 Hz, 1H), 2.37 (dd, J = 17.9, 5.4 Hz, 1H), 2.30 (q, J = 8.8 Hz, 1H), 2.25–2.20 (m, 1H), 2.13 (dd, J = 11.4, 8.8 Hz, 1H), 1.87–1.77 (m, 3H), 1.74 (t, J = 10.6 Hz, 2H), 1.13 (d, J = 6.7 Hz, 3H), 1.12–1.08 (m, 1H), 0.50 (q, J = 11.5 Hz, 1H); 13C NMR (200 MHz, DMSO-d6) δ 180.1, 169.7, 141.5, 133.4, 127.7, 124.5, 121.6, 109.3, 76.9, 70.5, 55.7, 53.5, 53.4, 39.0, 36.0, 34.7, 32.00, 28.0, 17.5.
Lactone 18. A mixture of keto-monoester 14 (11 mg, 0.03 mmol) and PtO2 (83%, 2 mg) in AcOH (2 mL) was stirred at room temperature under an atmosphere of hydrogen (1 atm) for 8 h. The mixture was filtered through a pad of Celite, and the filtrate was concentrated. The residue was purified by flash column chromatography on silica gel (DCM/acetone = 10[thin space (1/6-em)]:[thin space (1/6-em)]1) to give 18 (6 mg, 60%) as a colorless oil. 1H NMR (800 MHz, CDCl3): δ 7.68 (s, 1H), 7.35 (d, J = 7.4 Hz, 1H), 7.22 (t, J = 7.5 Hz, 1H), 7.05 (t, J = 7.5 Hz, 1H), 6.88 (d, J = 7.7 Hz, 1H), 4.16 (m, 1H), 3.34 (td, J = 8.6, 2.2 Hz, 1H), 3.29 (dd, J = 10.8, 3.9 Hz, 1H), 2.60–2.47 (m, 3H), 2.45–2.38 (m, 1H), 2.08–1.98 (m, 2H), 1.86 (t, J = 10.7 Hz, 1H), 1.48 (ddd, J = 21.5, 10.7, 4.1 Hz, 1H), 1.38 (d, J = 6.3 Hz, 3H), 1.31–1.28 (m, 2H), 0.68 (q, J = 11.7 Hz, 1H); 13C NMR (200 MHz, CDCl3): δ 180.9, 170.1, 140.0, 133.3, 128.1, 125.2, 122.8, 109.6, 80.0, 70.7, 56.5, 54.1, 53.8, 43.2, 36.7, 35.05, 34.8, 32.0, 20.0; HRMS (ESI) m/z calcd for C22H29N2O3S2 [M + H]+ 327.1703, found 327.1699. For observation of –NH: 1H NMR (800 MHz, DMSO-d6) δ 10.34 (–NH, s, 1H), 7.15 (d, J = 7.3 Hz, 1H), 7.09 (t, J = 7.6 Hz, 1H), 6.88 (t, J = 7.4 Hz, 1H), 6.75 (d, J = 7.7 Hz, 1H), 4.10 (m, 1H), 3.20 (d, J = 2.4 Hz, 1H), 3.14 (dd, J = 10.8, 4.0 Hz, 1H), 2.33 (dd, J = 17.8, 5.0 Hz, 1H), 2.29 (d, J = 8.8 Hz, 1H), 2.23 (dd, J = 11.2, 2.0 Hz, 1H), 2.14–2.10 (m, 1H), 1.88 (dd, J = 17.9, 12.5 Hz, 1H), 1.79 (d, J = 12.9 Hz, 1H), 1.69 (t, J = 10.8 Hz, 1H), 1.53 (d, J = 11.6 Hz, 1H), 1.31 (dd, J = 10.7, 4.0 Hz, 1H), 1.18 (d, J = 6.2 Hz, 3H), 1.03 (dd, J = 9.5, 2.9 Hz, 1H), 0.45 (q, J = 11.7 Hz, 1H); 13C NMR (200 MHz, DMSO-d6) δ 180.1, 169.6, 141.5, 133.4, 127.7, 124.5, 121.6, 109.3, 79.0, 70.4, 55.8, 53.5, 53.4, 42.2, 36.1, 34.5, 33.8, 31.3, 19.7.

Conflict of interest

The authors declare no competing financial interest.

Acknowledgements

This work was financially supported by the National Natural Science Foundation (U1502223) and National Basic Research Program of China (2011CB915503).

References

  1. J. S. Shi, J. X. Yu, X. P. Chen and R. X. Xu, Acta Pharmacol. Sin., 2003, 24, 97 CAS.
  2. G. Laus and K. Wurst, Helv. Chim. Acta, 2003, 86, 181 CrossRef CAS.
  3. Y. Ng, T. Or and N. Ip, Neurochem. Int., 2015, 89, 260 CrossRef CAS PubMed.
  4. A. Fu, K. Hung, H. Q. Huang, S. Gu, Y. Shen, E. Cheng, F. Ip, X. H. Huang, W. Fu and N. Ip, Proc. Natl. Acad. Sci. U. S. A., 2014, 111, 9959 CrossRef CAS PubMed.
  5. M. Tognolini, M. Incerti and A. Lodola, ACS Chem. Neurosci., 2014, 5, 1146 CrossRef CAS PubMed.
  6. Total synthesis of rhynchophylline and isorhynchophylline see: (a) Y. Ban, M. Seto and T. Oishi, Chem. Pharm. Bull., 1975, 23, 2605 CrossRef CAS; (b) Y. Ban, N. Taga and T. Oishi, Chem. Pharm. Bull., 1976, 24, 736 CrossRef CAS; (c) A. Deiters, M. Pettersson and S. F. Martin, J. Org. Chem., 2006, 71, 6547 CrossRef CAS PubMed; (d) H. Zhang, X. Ma, H. Kang, L. Hong and R. Wang, Chem.–Asian J., 2013, 8, 542 CrossRef CAS PubMed; (e) M. Amat, C. Ramos, M. Perez, E. Molins, P. Florindo, M. M. M. Santos and J. Bosch, Chem. Commun., 2013, 49, 1954 RSC; (f) M. J. Wanner, S. Ingemann, J. H. van Maarseveen and H. Hiemstra, Eur. J. Org. Chem., 2013, 79, 1100 CrossRef.
  7. J. Xu, L. D. Shao, D. Li, X. Deng, Y. C. Liu, Q. S. Zhao and C. Xia, J. Am. Chem. Soc., 2014, 136, 17962 CrossRef CAS PubMed.
  8. R. Oehl, G. Lenzer and P. Rosenmund, Chem. Ber., 1976, 109, 705 CrossRef CAS.
  9. R. A. Villa, Q. Xu and O. Kwon, Org. Lett., 2012, 14, 4634 CrossRef CAS PubMed.
  10. D. A. Evans, T. Rovis, M. C. Kozlowski, C. W. Downey and J. S. Tedrow, J. Am. Chem. Soc., 2000, 122, 9134 CrossRef CAS.
  11. H. L. Zhang, G. Zhao, Y. Ding and B. Wu, J. Org. Chem., 2005, 70, 4954 CrossRef CAS PubMed.
  12. H. Suginome, S. Yamada and J. B. Wang, J. Org. Chem., 1990, 55, 2170 CrossRef CAS.
  13. X. Pu and D. Ma, J. Org. Chem., 2003, 68, 4400 CrossRef CAS PubMed.
  14. C. Kuehm-Caubère, A. Guilmart, S. Adach-Becker, Y. Fort and P. Caubère, Tetrahedron Lett., 1998, 39, 8987 CrossRef.
  15. A. B. Smith and D. S. Kim, Org. Lett., 2004, 6, 1493 CrossRef CAS PubMed.

Footnote

Electronic supplementary information (ESI) available: NMR spectra for all isolated compounds. See DOI: 10.1039/c6ra12766e

This journal is © The Royal Society of Chemistry 2016